Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review
12:24pm, Monday, 24'th Feb 2025
On Monday, the FDA accepted the supplemental biologics license application (sBLA) for Bristol Myers Squibb & Co's BMY Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatmen
Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here
07:30am, Monday, 24'th Feb 2025
Despite significant market events, industrial and tech stocks have had similar returns since 2020, indicating a potential long-term rotation favoring value stocks. Higher inflation and interest rates
Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
03:36pm, Friday, 21'st Feb 2025
Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise is B
STOCKHOLM , Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from th
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant.
Buy 5 'Safer' Dividend Dogs Of 23 February Barron's Better Bets Than T-Bills
07:53am, Sunday, 16'th Feb 2025
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge d
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis.
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
04:16pm, Thursday, 13'th Feb 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial.
BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
02:56pm, Tuesday, 11'th Feb 2025
Bristol Myers' lackluster guidance for 2025 warrants caution. We recommend investors to wait and watch for the time being as generic competition for legacy drugs is a major headwind.
What's Going On With Bristol Myers Squibb Stock On Monday?
10:41am, Monday, 10'th Feb 2025
Bristol Myers Squibb & Co BMY released topline data Monday from its Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel) for relapsed or refractory indolent B-cell non-Hodgkin lymphoma
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
10:06am, Monday, 10'th Feb 2025
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook
08:15am, Monday, 10'th Feb 2025
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions. Despite a rece
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Announces Positive Topline Results for Breyanzi in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma.
Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
01:00pm, Friday, 07'th Feb 2025
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and concerns over patent expirations for key drugs. CEO Chris Boerner's multiyear plan focus
Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
07:27am, Friday, 07'th Feb 2025
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
